Cargando…

Concepts for agonistic targeting of CD40 in immuno-oncology

TNF Receptor Superfamily (TNF-R-SF) signaling is a structurally well-defined event that requires proper receptor clustering and trimerization. While the TNF-SF ligands naturally exist as trivalent functional units, the receptors are usually separated on the cell surface. Critically, receptor assembl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richards, David M., Sefrin, Julian P., Gieffers, Christian, Hill, Oliver, Merz, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7062441/ https://www.ncbi.nlm.nih.gov/pubmed/31403344 http://dx.doi.org/10.1080/21645515.2019.1653744

Ejemplares similares

A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
por: Thiemann, Meinolf, et al.
Publicado: (2018)

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023)

CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
por: Richards, David M, et al.
Publicado: (2021)

HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
por: Richards, David M., et al.
Publicado: (2019)

Discovery and Optimization of a Synthetic Class of Nectin-4-Targeted CD137 Agonists for Immuno-oncology
por: Upadhyaya, Punit, et al.
Publicado: (2022)

Concepts and Applications of Information Theory to Immuno-Oncology
por: Karolak, Aleksandra, et al.
Publicado: (2021)

Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro
por: Merz, Christian, et al.
Publicado: (2015)

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
por: Isaacs, James, et al.
Publicado: (2022)

Immuno-Oncology
por: Chaudhuri, Swapna
Publicado: (2017)

Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies
por: Viardot, Andreas, et al.
Publicado: (2020)

Radiomics in immuno-oncology
por: Bodalal, Z., et al.
Publicado: (2021)

CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development
por: Hashimoto, Kenji
Publicado: (2021)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology
por: Ji, Yan, et al.
Publicado: (2018)

Multiplex imaging in immuno-oncology
por: Zhao, Chen, et al.
Publicado: (2023)

Immuno-PET Imaging of Atherosclerotic Plaques with [(89)Zr]Zr-Anti-CD40 mAb—Proof of Concept
por: Poels, Kikkie, et al.
Publicado: (2022)

Immunotherapies and Combination Strategies for Immuno-Oncology
por: Barbari, Cody, et al.
Publicado: (2020)

Necroptosis in Immuno-Oncology and Cancer Immunotherapy
por: Sprooten, Jenny, et al.
Publicado: (2020)

Virus-Based Immuno-Oncology Models
por: Sitta, Juliana, et al.
Publicado: (2022)

Organoids as an Enabler of Precision Immuno-Oncology
por: Zhao, Junzhe, et al.
Publicado: (2023)

Single-Cell Analysis in Immuno-Oncology
por: Christodoulou, Maria-Ioanna, et al.
Publicado: (2023)

The Role of PRMT5 in Immuno-Oncology
por: Abe, Yoshinori, et al.
Publicado: (2023)

Immuno-Oncology: Emerging Targets and Combination Therapies
por: Marshall, Henry T., et al.
Publicado: (2018)

Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
por: Holmen Olofsson, Gitte, et al.
Publicado: (2020)

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends
por: Posa, Alessandro, et al.
Publicado: (2023)

Immuno-oncology for B-cell lymphomas
por: Choi, Yoon Seok
Publicado: (2021)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

The Role of Radiation Oncology in Immuno‐Oncology
por: Meng, Xiangjiao, et al.
Publicado: (2019)

Radiotherapy as a New Player in Immuno-Oncology
por: Wang, Shang-Jui, et al.
Publicado: (2018)

Theranostics in immuno-oncology using nanobody derivatives
por: Lecocq, Quentin, et al.
Publicado: (2019)

Carbon Nanomaterials: Emerging Roles in Immuno-Oncology
por: Patrick, Bbumba, et al.
Publicado: (2023)

Immuno-oncology-microbiome axis of gastrointestinal malignancy
por: Lin, Quan, et al.
Publicado: (2023)

TCR sequencing: applications in immuno-oncology research
por: Sanromán, Á.F., et al.
Publicado: (2023)

Immuno-oncology approaches in uveal melanoma: tebentafusp and beyond
por: Gerard, C., et al.
Publicado: (2023)

Immuno-Oncology Medicines: Policy Implications and Economic Considerations
por: Adunlin, Georges, et al.
Publicado: (2019)

The CD40-CD40L Dyad as Immunotherapeutic Target in Cardiovascular Disease
por: Bosmans, Laura A., et al.
Publicado: (2020)

Role of AI and digital pathology for colorectal immuno-oncology
por: Bilal, Mohsin, et al.
Publicado: (2022)

Current markers and their value in the era of immuno-oncology
por: von Rundstedt, Friedrich-Carl, et al.
Publicado: (2017)

Advancing translational research for colorectal immuno-oncology
por: Thomas, Elaine M., et al.
Publicado: (2023)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_334fpnuvgrbcue086e1lm6co1f